{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:09:34Z","timestamp":1794215374760,"version":"4.8.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tice.2025.102783","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T15:59:14Z","timestamp":1739030354000},"page":"102783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Clinical and immunohistochemical effects of OncoTherad (MRB-CFI-1) nanoimmunotherapy on SERBP1, HABP4, CD44 and Ki-67 in BCG-unresponsive non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"93","author":[{"given":"Maria Izabel de Barros Fraz\u00e3o","family":"Salmazo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Carlos Cardoso","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Cardoso","family":"de Arruda Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"da Silva Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monaliza","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora Manzato","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Luiz Lopes","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martim Corr\u00eaa","family":"Bottene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Felipe Prodocimo","family":"Lestingi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Henrique Ferreira","family":"Caria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kobarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner Jos\u00e9","family":"F\u00e1varo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2025.102783_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.tice.2025.102783_bib2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1464-410x.1998.00628.x","article-title":"The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index","volume":"81","author":"Allard","year":"1998","journal-title":"Br. J. Urol."},{"issue":"24","key":"10.1016\/j.tice.2025.102783_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417535","article-title":"OncoTherad\u00ae (MRB-CFI-1) nanoimmunotherapy: a promising strategy to treat Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: crosstalk among T-cell CX3CR1, immune checkpoints, and the toll-like receptor 4 signaling pathway","volume":"24","author":"Alonso","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tice.2025.102783_bib4","series-title":"What are the key statistics about bladder cancer?","article-title":"Overview: bladder cancer","author":"American Cancer Society","year":"2024"},{"key":"10.1016\/j.tice.2025.102783_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00255833","article-title":"In vitro chemosensitivity of J-82 human bladder cancer cells","volume":"14","author":"Anderson","year":"1986","journal-title":"Urol. Res."},{"key":"10.1016\/j.tice.2025.102783_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib7","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1323\/1\/012022","article-title":"New therapeutic perspective for bladder cancer in dogs: toxicological and clinical effects of oncotherad nanostructured immunotherapy","volume":"1323","author":"B\u00f6ckelmann","year":"2019","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.tice.2025.102783_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051364","article-title":"A comprehensive analysis of immune response in patients with non-muscle-invasive bladder cancer","volume":"15","author":"Celada Luis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tice.2025.102783_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MOU.0b013e32833cc9df","article-title":"Cancer stem cells in bladder cancer: a revisited and evolving concept","volume":"20","author":"Chan","year":"2010","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.tice.2025.102783_bib11","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.7314\/APJCP.2012.13.5.2229","article-title":"A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer","volume":"13","author":"Chen","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.tice.2025.102783_bib12","article-title":"The prognostic value and immunological role of CD44 in pan-cancer study","volume":"13","author":"Chen","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tice.2025.102783_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4331\/wjbc.v10.i3.44","article-title":"Complex interactomes and post-translational modifications of the regulatory proteins HABP4 and SERBP1 suggest pleiotropic cellular functions","volume":"10","author":"Colleti","year":"2019","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.tice.2025.102783_bib14","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.bbamcr.2014.08.016","article-title":"Ki-1\/57 and CGI-55 ectopic expression impact cellular pathways involved in proliferation and stress response regulation","volume":"1843","author":"Costa","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tice.2025.102783_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12032-024-02533-z","article-title":"Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases","volume":"41","author":"De Arruda Camargo","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/omi.2021.0025","article-title":"Cancer stem cell marker CD44 plays multiple key roles in human cancers: immune suppression\/evasion, drug resistance, epithelial-mesenchymal transition, and metastasis","volume":"25","author":"Dzobo","year":"2021","journal-title":"OMICS"},{"key":"10.1016\/j.tice.2025.102783_bib17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11255-020-02480-4","article-title":"Urinary hyaluronic acid: a versatile marker of bladder cancer","volume":"52","author":"El-Hefnawy","year":"2020","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.tice.2025.102783_bib18","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urologic Pathology consensus classification of urothelial (transitional) neoplasms of the urinary bladder","volume":"22","author":"Epstein","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.tice.2025.102783_bib19","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/ijc.29134","article-title":"A brief history of cancer: age-old milestones underlying our current knowledge database","volume":"136","author":"Faguet","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.tice.2025.102783_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e16004","article-title":"Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK\/RANKL signaling: new therapeutic perspective for non-muscle invasive bladder cancer","volume":"37","author":"F\u00e1varo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib21","unstructured":"F\u00e1varo W.J., Dur\u00e1n-Caballero N.E.. Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. U.S. Patent 16\/617,493, 10 May 2021."},{"key":"10.1016\/j.tice.2025.102783_bib22","unstructured":"F\u00e1varo W.J., Dur\u00e1n-Caballero N.E. Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. U.S. Patent 17\/236,861, 5 February 2023a."},{"key":"10.1016\/j.tice.2025.102783_bib23","unstructured":"F\u00e1varo W.J., Dur\u00e1n-Caballero N.E. Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. U.S. Patent 17\/236,839, 11 April 2023b."},{"key":"10.1016\/j.tice.2025.102783_bib24","unstructured":"F\u00e1varo W.J., Dur\u00e1n-Caballero N.E. Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. U.S. Patent 17\/236,848, 2 July 2023c."},{"key":"10.1016\/j.tice.2025.102783_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2022.101988","article-title":"New synthetic nano-immunotherapy (OncoTherad\u00ae) for non-muscle invasive bladder cancer: its synthesis, characterization and anticancer property","volume":"80","author":"F\u00e1varo","year":"2023","journal-title":"Tissue Cell"},{"key":"10.1016\/j.tice.2025.102783_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.707025","article-title":"Current status of canine melanoma diagnosis and therapy: report from a colloquium on canine melanoma organized by ABROVET (Brazilian Association of Veterinary Oncology)","volume":"8","author":"Fonseca-Alves","year":"2021","journal-title":"Front Vet. Sci."},{"key":"10.1016\/j.tice.2025.102783_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI41004","article-title":"The therapeutic promise of the cancer stem cell concept","volume":"120","author":"Frank","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tice.2025.102783_bib28","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bju.12263","article-title":"Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma","volume":"113","author":"Gayed","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.tice.2025.102783_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000351961","article-title":"Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?","volume":"92","author":"Gontero","year":"2014","journal-title":"Urol. Int"},{"key":"10.1016\/j.tice.2025.102783_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/srep36869","article-title":"Progesterone receptor membrane component 1 mediates progesterone-induced suppression of oocyte meiotic prophase I and primordial folliculogenesis","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tice.2025.102783_bib31","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4149\/neo_2012_089","article-title":"Stem cells in the biology of normal urothelium and urothelial carcinoma","volume":"59","author":"Hatina","year":"2012","journal-title":"Neoplasma"},{"issue":"9","key":"10.1016\/j.tice.2025.102783_bib32","first-page":"347","article-title":"The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms","volume":"3","author":"Haynes","year":"1991","journal-title":"Cancer Cells"},{"key":"10.1016\/j.tice.2025.102783_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/pin.13060","article-title":"Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer","volume":"71","author":"Ikeda","year":"2021","journal-title":"Pathol. Int."},{"key":"10.1016\/j.tice.2025.102783_bib34","series-title":"Estimativa 2023: incid\u00eancia de c\u00e2ncer no Brasil. Instituto Nacional de C\u00e2ncer","author":"Instituto Nacional de C\u00e2ncer (Brasil)","year":"2022"},{"key":"10.1016\/j.tice.2025.102783_bib35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/mc.22300","article-title":"Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer","volume":"55","author":"Islam","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.tice.2025.102783_bib36","first-page":"2530","article-title":"Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics","volume":"44","author":"Kovnat","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.tice.2025.102783_bib37","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.juro.2014.11.007","article-title":"Multinstitutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract","volume":"193","author":"Krabbe","year":"2015","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2025.102783_bib38","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/cncr.25565","article-title":"Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis","volume":"117","author":"Kramer","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.tice.2025.102783_bib39","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0022-5347(17)53283-8","article-title":"Bladder cancer immunotherapy","volume":"128","author":"Lamm","year":"1982","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.tice.2025.102783_bib40","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000471723","article-title":"Intratumoral heterogeneity of DNA indexes in transitional cell bladder cancer: relation to tumor histology","volume":"20","author":"Lipponen","year":"1991","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tice.2025.102783_bib42","article-title":"CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis","volume":"13","author":"Liu","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.tice.2025.102783_bib43","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3892\/ijo.2017.4111","article-title":"SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB\/NF-\u03baB axis","volume":"51","author":"Ma","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4111\/kju.2015.56.1.31","article-title":"Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study","volume":"56","author":"Makboul","year":"2015","journal-title":"Korean J. Urol."},{"key":"10.1016\/j.tice.2025.102783_bib45","first-page":"43","article-title":"Non-muscle-invasive bladder cancer: Overview and contemporary treatment landscape of neoadjuvant chemoablative therapies","volume":"22","author":"Matulewicz","year":"2020","journal-title":"Rev. Urol."},{"key":"10.1016\/j.tice.2025.102783_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.tice.2025.102783_bib47","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.18632\/oncotarget.27804","article-title":"Intracellular hyaluronic acid-binding protein 4 (HABP4): a candidate tumor suppressor in colorectal cancer","volume":"11","author":"Melo-Hanchuk","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.tice.2025.102783_bib48","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/bjc.2017.318","article-title":"Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets","volume":"117","author":"Morera","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.tice.2025.102783_bib49","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.cellsig.2015.05.002","article-title":"CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells","volume":"27","author":"Nam","year":"2015","journal-title":"Cell Signal."},{"key":"10.1016\/j.tice.2025.102783_bib50","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbrc.2006.01.036","article-title":"Evidence for the interaction of the regulatory protein Ki-1\/57 with p53 and its interacting proteins","volume":"341","author":"Nery","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tice.2025.102783_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/(SICI)1097-0215(19960410)66:2<255::AID-IJC20>3.0.CO;2-A","article-title":"Suppression of CD44 expression decreases migration and invasion of human glioma cells","volume":"66","author":"Okada","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tice.2025.102783_bib52","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cncr.30392","article-title":"Non-muscle-invasive bladder cancer: intravesical treatments beyond Bacille Calmette-Guerin","volume":"123","author":"Packiam","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.tice.2025.102783_bib53","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4111\/kju.2011.52.7.466","article-title":"Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study","volume":"52","author":"Park","year":"2011","journal-title":"Korean J. Urol."},{"key":"10.1016\/j.tice.2025.102783_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: from adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tice.2025.102783_bib55","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1007\/s00432-022-04449-5","article-title":"OncoTherad\u00ae is an immunomodulator of biological response that downregulate RANK\/RANKL signaling pathway and PD-1\/PD-L1 immune checkpoint in non-muscle invasive bladder cancer","volume":"149","author":"Reis","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2022.101747","article-title":"Effects of combined OncoTherad immunotherapy and probiotic supplementation on modulating the chronic inflammatory process in colorectal carcinogenesis","volume":"75","author":"Reis","year":"2022","journal-title":"Tissue Cell"},{"key":"10.1016\/j.tice.2025.102783_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110723","article-title":"A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad\u00ae immunotherapy associated with platelet-rich plasma","volume":"123","author":"Ribeiro de Souza","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.tice.2025.102783_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117755","article-title":"A novel serous ovarian carcinoma model induced by DMBA: results from OncoTherad (MRB-CFI-1) immunotherapy preclinical testing","volume":"182","author":"Ribeiro de Souza","year":"2025","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.tice.2025.102783_bib59","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","article-title":"Cancer-specific survival of patients with non-muscle-invasive bladder cancer: A population-based analysis","volume":"30","author":"\u015alusarczyk","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.tice.2025.102783_bib60","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle-invasive bladder cancer\u2014therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr. Urol. Rep."},{"issue":"6","key":"10.1016\/j.tice.2025.102783_bib61","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.21037\/tau.2017.11.10","article-title":"Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder","volume":"6","author":"Vetterlein","year":"2017","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.tice.2025.102783_bib62","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.2147\/OTT.S250355","article-title":"lncRNA TMPO-AS1 exerts oncogenic roles in HCC through regulating miR-320a\/SERBP1 axis","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther."},{"issue":"7","key":"10.1016\/j.tice.2025.102783_bib63","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.7150\/jca.18297","article-title":"Impact of CD44 expression on radiation response for bladder cancer","volume":"8","author":"Wu","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.tice.2025.102783_bib64","first-page":"458.e1","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol. Oncol. Semin Orig. Invest."},{"key":"10.1016\/j.tice.2025.102783_bib65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12015-008-9047-8","article-title":"Enrichment of cancer stem cells based on heterogeneity of invasiveness","volume":"5","author":"Yu","year":"2009","journal-title":"Stem Cell Rev."},{"issue":"4","key":"10.1016\/j.tice.2025.102783_bib66","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","author":"Zoller","year":"2011","journal-title":"Nat. Rev. Cancer"}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T23:39:20Z","timestamp":1740785960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816625000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":66,"alternative-id":["S0040816625000631"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2025.102783","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and immunohistochemical effects of OncoTherad (MRB-CFI-1) nanoimmunotherapy on SERBP1, HABP4, CD44 and Ki-67 in BCG-unresponsive non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2025.102783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102783"}}